血管紧张素-脑啡肽酶抑制与射血分数保留心衰患者的肾脏结局
PARAGON-HF试验纳入4822例射血分数保留心衰患者,随机接受沙库巴曲/缬沙坦或缬沙坦治疗。结果显示沙库巴曲/缬沙坦组肾脏复合终点发生33例(1.4%),缬沙坦组64例(2.7%),风险比0.50(95%CI 0.33-0.77;P=0.001),且eGFR下降更慢。
要点
- 沙库巴曲/缬沙坦较缬沙坦降低肾脏复合终点风险50%。
- 沙库巴曲/缬沙坦延缓eGFR下降速度。
- 肾脏获益不受基线eGFR水平影响。
核心结论
- 在射血分数保留心衰患者中,沙库巴曲/缬沙坦较缬沙坦降低肾脏事件风险并减缓eGFR下降。
研究设计与样本
- 随机、双盲、事件驱动试验(PARAGON-HF),纳入4822例射血分数保留心衰患者,沙库巴曲/缬沙坦组2419例,缬沙坦组2403例。
主要发现
- 随机化时eGFR为63±19 mL·min-1·1.73 m-2。
- 研究结束时,肾脏复合终点在沙库巴曲/缬沙坦组发生33例(1.4%),缬沙坦组64例(2.7%),风险比0.50(95%CI 0.33-0.77;P=0.001)。
- eGFR下降幅度沙库巴曲/缬沙坦组为-2.0(95%CI -2.2至-1.9)mL·min-1·1.73 m-2/年,缬沙坦组为-2.7(95%CI -2.8至-2.5)mL·min-1·1.73 m-2/年。
- 基线eGFR<60与≥60 mL·min-1·1.73 m-2亚组间,复合肾脏终点的治疗效应无差异(P-interaction=0.92)。
临床怎么用
- 对于射血分数保留心衰患者,沙库巴曲/缬沙坦可考虑用于降低肾脏事件风险并延缓肾功能下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with heart failure, chronic kidney disease is common and associated with a higher risk of renal events than in patients without chronic kidney disease. We assessed the renal effects of angiotensin/neprilysin inhibition in patients who have heart failure with preserved ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction). METHODS: In this randomized, double-blind, event-driven trial, we assigned 4822 patients who had heart failure with preserved ejection fraction to receive sacubitril/valsartan (n=2419) or valsartan (n=2403). Herein, we present the results of the prespecified renal composite outcome (time to first occurrence of either: ≥50% reduction in estimated glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individual components of this composite, and the influence of therapy on eGFR slope. RESULTS: At randomization, eGFR was 63±19 mL·min-1·1.73 m-2. At study closure, the composite renal outcome occurred in 33 patients (1.4%) assigned to sacubitril/valsartan and 64 patients (2.7%) assigned to valsartan (hazard ratio, 0.50 [95% CI, 0.33-0.77]; P=0.001). The treatment effect on the composite renal end point did not differ according to the baseline eGFR (<60 versus ≥60 mL·min-1·1.73 m-2 (P-interaction=0.92). The decline in eGFR was less for sacubitril/valsartan than for valsartan (-2.0 [95% CI, -2.2 to -1.9] versus -2.7 [95% CI, -2.8 to -2.5] mL·min-1·1.73 m-2 per year). CONCLUSIONS: In patients with heart failure with preserved ejection fraction, sacubitril/valsartan reduced the risk of renal events, and slowed decline in eGFR, in comparison with valsartan. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.
引用
- Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020. PMID: 32845715. doi:10.1161/CIRCULATIONAHA.120.047643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。